Effervescent tablet subsidised for eosinophilic oesophagitis
The formulation increases the length of time damaged mucosa is exposed to a topical steroid
A newly PBS-listed oral therapy will likely become first-line for adults with eosinophilic oesophagitis who require a topical steroid, a leading gastroenterologist says.
Previously, such patients had to contend with off-label use of inhaled corticosteroids intended for asthma control, which was not ideal for delivery to the oesophagus.
Since 1 May, patients living with the chronic, immune-mediated oesophageal disease are eligible for subsidised budesonide in an orally disintegrating tablet
